Last reviewed 2026-04-20 · How we verify

PF-06801591 (pf-06801591)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Constipation
• Nausea
• Vomiting
• Generalised oedema
• Mucosal inflammation
• Urinary tract infection
• Blood creatinine increased
• Decreased appetite
• Back pain
• Hypothyroidism
• Conjunctival haemorrhage
• Abdominal distension

Key clinical trials

• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (PHASE1)
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies (PHASE1)
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (PHASE1, PHASE2)
• A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
• A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (PHASE1)
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (PHASE1)
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.